RE: Highly regarded Wall Street healthcare analyst £5 target29 May 2020 14:32
Just to think current broker target of £5 is present position, once foralumab Milciclib antiIL6r reach final phase ready for market you could see broker targets increase far higher towards £9++ add on the free shares from StemPrintER its good news short and long term